LIGAND PHARMACEUTICALS INC 8-K

What Happened

• Ligand Pharmaceuticals Incorporated announced its financial results for the three months ended March 31, 2026 by issuing a press release on May 7, 2026. The press release is furnished as Exhibit 99.1 to the company's Form 8-K filing. The Form 8-K was signed by Andrew Reardon, Chief Legal Officer and Secretary.

Key Details

• Item reported: 2.02 — Results of Operations and Financial Condition (press release announcing quarterly results).
• Reporting date: May 7, 2026; period covered: three months ended March 31, 2026.
• Exhibit included: 99.1 — press release dated May 7, 2026.
• The company states the information in this 8-K (including Exhibit 99.1) is furnished, not “filed,” and therefore is not subject to Section 18 liability or automatically incorporated by reference in other filings.

Why It Matters

• Quarterly results provide investors key information on earnings, revenue and the company’s financial condition that can affect stock price and investor decisions.
• This 8-K signals that detailed quarterly figures and commentary are available in the attached press release (Exhibit 99.1); investors should review that press release for specific revenue, profit/loss, and management commentary.
• The filing’s disclosure that the release is “furnished” (not “filed”) is a standard legal note about liability and does not change the substantive financial information provided.